Stay updated on Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page.

Latest updates to the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page
- Check5 days agoChange DetectedTwo new sites were added: Malmö, Skåne County, Sweden, 205 02 and Taoyuan, Taiwan, 333; two existing entries were removed/renamed: Malmo, Skåne County, Sweden, 205 02 and Taoyuan District, Taiwan, 333. This update reflects the updated geographic identifiers for trial locations.SummaryDifference0.0%

- Check12 days agoChange DetectedResults have been posted for the study, including primary and secondary outcomes (e.g., RFS and OS definitions and time frames), adverse events, and quality-of-life measures. The update also references the Study Protocol and Statistical Analysis Plan and lists the results reporting dates.SummaryDifference1.0%

- Check20 days agoChange DetectedClinicalTrials.gov’s page revision/version label was updated from **v3.5.2** to **v3.5.3**.SummaryDifference0.0%

- Check27 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check48 days agoChange DetectedThe Locations entry changed from Napoli, Italy, 80147 to Naples, Italy, 80147.SummaryDifference0.0%

- Check56 days agoChange DetectedAdded a new resource entry for the Genetic and Rare Diseases Information Center under Resources. Updated the revision from v3.4.3 to v3.5.0.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page.